Securities code: 600513 securities abbreviation: Jiangsu Lianhuan Pharmaceutical Co.Ltd(600513) Announcement No.: 2022-007
Jiangsu Lianhuan Pharmaceutical Co.Ltd(600513)
Announcement on Amending the articles of Association
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or
And shall be individually and jointly liable for the authenticity, accuracy and completeness of its contents.
Jiangsu Lianhuan Pharmaceutical Co.Ltd(600513) (hereinafter referred to as the “company” and ” Jiangsu Lianhuan Pharmaceutical Co.Ltd(600513) “) was established on January 2022
On January 21, the second interim meeting of the eighth board of directors was held, which deliberated and adopted the report on the company’s restricted shares in 2019
Discussion on the unfulfilled conditions for the first lifting of the sales restriction period of the ticket incentive plan and the repurchase and cancellation of some restricted shares
Proposal on Amending the articles of association. As the company’s restricted stock incentive plan in 2019 is partially limited
The repurchase and cancellation of institutional shares will reduce the registered capital, and the relevant provisions in the articles of association will be revised. See the specific circumstances
As follows:
Original clause modified clause
Article 6 the registered capital of the company is RMB 287 million. Article 6 the registered capital of the company is RMB 287 million nine hundred and ninety thousand three hundred and seventy (RMB 287990370). One hundred and forty-five thousand six hundred and seventy-four yuan (RMB 287145674).
Article 27 the total number of shares of the company is 287.99037 million. Article 27 the total number of shares of the company is 287145674
The share capital structure of the company is 28799037 ordinary shares. The share capital structure of the company is 287145674 ordinary shares.
In addition to the above amendments, other provisions in the articles of association remain unchanged, and the above amendments have been adopted by the company for the eighth session
The second extraordinary meeting of the board of directors shall be deliberated and approved, and it shall be submitted to the general meeting of shareholders of the company for deliberation and special resolution
Approved by more than two-thirds of the voting rights held by the shareholders attending the meeting. See the above for the revised articles of association
Website of Shanghai Stock Exchange (http: / / www.sse. Com. CN.).
It is hereby announced.
Jiangsu Lianhuan Pharmaceutical Co.Ltd(600513) board of directors
January 22, 2022
